Sign in

CIK 0001231457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
  1. 4 Grant or award General Counsel acquired 10,708 shares (grant or award)
  2. 4 Grant or award President and CEO acquired 30,339 shares (grant or award)
  3. 4 Derivatives Options or other derivatives
  4. 3 Insider Initial Statement of Ownership
  5. 4/A Derivatives Options or other derivatives
  6. 4/A Derivatives Options or other derivatives
  7. 4/A Derivatives Options or other derivatives
  8. 4/A Derivatives Options or other derivatives
  9. 4 Open-market sale Director sold 3,460 shares at $2.46 ($8,512)
  10. 4 Grant or award Head of Regulatory acquired 15,525 shares (grant or award)
  11. 4 Grant or award General Counsel acquired 22,000 shares (grant or award)
  12. 4 Grant or award VP, Clinical Trial Operations acquired 29,000 shares (grant or award)
  13. 4 Grant or award VP, Pharmaceutical Development acquired 29,000 shares (grant or award)
  14. 4 Grant or award Chief Financial Officer acquired 41,650 shares (grant or award)
  15. 4 Grant or award President and CEO acquired 134,500 shares (grant or award)
  16. 4 Open-market sale President and CEO sold 14,315 shares at $2.34 ($33,497)
  17. 4 Open-market sale Chief Financial Officer sold 2,103 shares at $2.34 ($4,921)
  18. 4 Open-market sale Head of Regulatory sold 2,510 shares at $2.34 ($5,873)
  19. 4 Open-market sale VP, Pharmaceutical Development sold 6,300 shares at $2.34 ($14,742)
  20. 4 Derivatives Options or other derivatives

Page 4 of 10 · 190 filings